-
In this downloadable slideset, Ira M. Jacobson, MD, and Paul Y. Kwo, MD, review optimal management of patients with HCV who have achieved SVR, including recommendations for HCV RNA and HCC monitoring.
-
In this updated slideset for primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment.
-
Eliminating HCV infection among persons who inject drugs is a daunting task whether tackling it from a patient care perspective, through practice transformation, or by influencing policies that improve access to treatment. Nonetheless, there are practical steps that can be taken by clinicians to improve the HCV continuum of care for this challenging population. Here’s my take on some of those steps.
-
Listen to downloadable audio from a series of live Webinars by Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, in which the clinical impact of new data reported at the Washington, DC meeting is discussed.
-
With the approvals of SOF/VEL/VOX and GLE/PIB, what is the new management approach for DAA-experienced patients with HCV infection?
|
Latest Content
-
Overall SVR12 rate of 96% with no study drug–related serious adverse events at interim analysis.
Date Posted: 4/19/2018
-
Among 3 patients who relapsed without achieving SVR12, all had resistance associated substitutions.
Date Posted: 4/19/2018
-
96% SVR4 in noncirrhotic NS5A-experienced patients receiving 12-week, RBV-free regimen.
Date Posted: 4/18/2018
-
Fewer relapses with inclusion of RBV, particularly in patients with baseline NS5A RAS.
Date Posted: 4/15/2018
-
| Paul Y. Kwo MD - 2/14/2018 |
|
Which patients, who have achieved a sustained virologic response with HCV treatment, need to be screened for hepatocellular carcinoma? Here’s my approach.
-
Listen to downloadable audio from a series of live Webinars by Ira M. Jacobson, MD, and Paul Y. Kwo, MD, in which the optimal management of patients with HCV who have achieved SVR is discussed and audience questions are answered.
Date Posted: 2/14/2018
-
In this downloadable slideset, Ira M. Jacobson, MD, and Paul Y. Kwo, MD, review optimal management of patients with HCV who have achieved SVR, including recommendations for HCV RNA and HCC monitoring.
Date Posted: 2/6/2018
-
In this updated slideset for primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment.
Date Posted: 2/2/2018
-
| Frederick L. Altice MD - 1/19/2018 |
|
Eliminating HCV infection among persons who inject drugs is a daunting task whether tackling it from a patient care perspective, through practice transformation, or by influencing policies that improve access to treatment. Nonetheless, there are practical steps that can be taken by clinicians to improve the HCV continuum of care for this challenging population. Here’s my take on some of those steps.
-
In this updated CME-certified interactive presentation targeted to primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment.
Faculty: Terry D. Box MD, Brian L. Pearlman MD, FACP, FAASLD, Mary Speigle NP
Released: 1/17/2018
|
|
|